Cart
sales@molnova.com
Officinalisinin I
CAS No. 57944-18-0
Officinalisinin I( —— )
Catalog No. M18844 CAS No. 57944-18-0
Officinalisinin I can effectively reduce the blood glucose and protect nerve injuryin diabetic mice.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 133 | In Stock |
|
| 5MG | 86 | In Stock |
|
| 10MG | 122 | In Stock |
|
| 25MG | 204 | In Stock |
|
| 50MG | 296 | In Stock |
|
| 100MG | 436 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOfficinalisinin I
-
NoteResearch use only, not for human use.
-
Brief DescriptionOfficinalisinin I can effectively reduce the blood glucose and protect nerve injuryin diabetic mice.
-
DescriptionOfficinalisinin I can effectively reduce the blood glucose and protect nerve injuryin diabetic mice.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetERK
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number57944-18-0
-
Formula Weight921.07
-
Molecular FormulaC45H76O19
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (108.57 mM)
-
SMILESC[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC[C@H]5[C@@]4(CC[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)C)OC1(CC[C@H](C)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Liu J, et al. Study on hypoglycemic mechanism and central nerve protection of Officinalisinin I in Rhizoma Anemarrhenae[J]. China Journal of Traditional Chinese Medicine & Pharmacy, 2017.
molnova catalog
related products
-
Mogrol
Mogrol is a biometabolite of mogrosides. Mogrol acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.
-
AZD0364
AZD0364 (AZD-0364) is a potent, selective, orally active ERK1/2 inhibitor for treatment of NSCLC.
-
BAY885
BAY885 is a new ERK5 inhibitor.
